HLA-DR9 restrictive regulatory T cell epitope of Hepatitis B virus core antigen and e antigen and application thereof

A technology of HLA-DR9 and core antigens, applied in the field of regulatory T cell epitopes, to achieve efficient inhibition and clearance, rebuild cellular immune function, and break the effect of HBV immune tolerance

Inactive Publication Date: 2011-01-12
ARMY MEDICAL UNIV
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, whether protein antigens derived from HBV such as HBcAg and HBeAg are involved in the induc

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • HLA-DR9 restrictive regulatory T cell epitope of Hepatitis B virus core antigen and e antigen and application thereof
  • HLA-DR9 restrictive regulatory T cell epitope of Hepatitis B virus core antigen and e antigen and application thereof
  • HLA-DR9 restrictive regulatory T cell epitope of Hepatitis B virus core antigen and e antigen and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0021] Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the accompanying drawings. The concentrations of candidate epitope peptides or irrelevant control peptides, IL-2, anti-CD28, anti-HLA-DR and anti-CD3 antibody (anti-CD3) mentioned in the examples all refer to their final concentrations in the mixture.

[0022] 1. Pan-restricted CD4 + Analysis of T cell epitope hotspots and synthesis of candidate epitope peptides

[0023] Obtain existing CD4 from the epitope database (http: / / www.immunepitope.org / ) +T cell epitopes, according to relevant literature reports and online software MHCPred (http: / / research.i2r.a-star.edu.sg / multipre / ) and SYFPEITHI (http: / / www.syfpeithi.de / ) to predict HBcAg Treg epitopes. Since HBeAg and HBcAg have a common sequence of 70%, HBeAg in serum can be regarded as the secreted type of HBcAg. Therefore, the present invention uses three peptides in the common sequence of HBeAg and HBcAg as candi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an HLA-DR9 restrictive regulatory T cell epitope of Hepatitis B virus core antigen and e antigen, which is composed of the following amino acid sequence: SRDLVVNYVNTNMGLKIRQLLWFHI. The invention also discloses an application of a regulatory T cell epitope in preparing hepatitis B therapeutic vaccine containing the Hepatitis B virus core antigen and e antigen, namely when the hepatitis B therapeutic vaccine containing the Hepatitis B virus core antigen and/or e antigen is prepared, the regulatory T cell epitope with immunosuppressive action in the Hepatitis B virus coreantigen and/or e antigen is eliminated. The invention provides a new strategy and a method for development of the high-efficient hepatitis B therapeutic vaccine, is expected to break hepatitis B immune tolerance, rebuilds cellular immune function and effectively inhibits and eliminates the hepatitis B virus.

Description

technical field [0001] The present invention relates to a regulatory T cell (Treg) epitope, in particular to the HLA-DR9 restricted Treg epitope of hepatitis B virus core antigen (HBcAg) and hepatitis B virus e antigen (HBeAg), and also relates to the application of the Treg epitope . Background technique [0002] Hepatitis B virus (HBV) infection is widespread worldwide and poses a serious threat to human health. Anti-HBV specific immune response plays a decisive role in eliminating HBV from the body. Multiple studies report detection of active virus-specific CD4 in recoverers of acute HBV infection + and CD8 + T cell responses, whereas only weak virus-specific T cell responses were observed in patients with chronic HBV infection (CHB). CD4 + CD25 + Foxp3 + Treg has been shown to suppress other CD4 + T cells and CD8 + The activation and proliferation of T cells play an important role in maintaining normal peripheral immune tolerance. Current studies have shown tha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K14/02A61K39/29A61P1/16A61P31/20
Inventor 王莉张梦军吴玉章
Owner ARMY MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap